129 related articles for article (PubMed ID: 9457401)
1. Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.
Gold PJ; Thompson JA; Markowitz DR; Neumann S; Fefer A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S85-91. PubMed ID: 9457401
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
4. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
6. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
[TBL] [Abstract][Full Text] [Related]
9. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma.
Palmer PA; Atzpodien J; Philip T; Negrier S; Kirchner H; Von der Maase H; Geertsen P; Evers P; Loriaux E; Oskam R
Cancer Biother; 1993; 8(2):123-36. PubMed ID: 7804353
[TBL] [Abstract][Full Text] [Related]
10. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
Yang JC; Rosenberg SA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.
Foon KA; Walther PJ; Bernstein ZP; Vaickus L; Rahman R; Watanabe H; Sweeney J; Park J; Vesper D; Russell D
J Immunother (1991); 1992 Apr; 11(3):184-90. PubMed ID: 1515423
[TBL] [Abstract][Full Text] [Related]
12. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
[TBL] [Abstract][Full Text] [Related]
13. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.
Palmer PA; Vinke J; Evers P; Pourreau C; Oskam R; Roest G; Vlems F; Becker L; Loriaux E; Franks CR
Eur J Cancer; 1992; 28A(6-7):1038-44. PubMed ID: 1627369
[TBL] [Abstract][Full Text] [Related]
14. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group.
Dillman RO; Wiemann MC; Bury MJ; Church C; DePriest C
Cancer Biother Radiopharm; 1997 Feb; 12(1):5-11. PubMed ID: 10851441
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
[TBL] [Abstract][Full Text] [Related]
16. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
Shulman KL; Stadler WM; Vogelzang NJ
Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
[TBL] [Abstract][Full Text] [Related]
18. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.
Dillman RO; Oldham RK; Tauer KW; Orr DW; Barth NM; Blumenschein G; Arnold J; Birch R; West WH
J Clin Oncol; 1991 Jul; 9(7):1233-40. PubMed ID: 2045864
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
20. High-dose aldesleukin in renal cell carcinoma: long-term survival update.
Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Fyfe G
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S70-2. PubMed ID: 9457398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
